LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Real‐world experience and analyses of the performance of ixekizumab as first‐line biologic agent versus second‐line (or higher) biologic agent in the treatment of chronic plaque psoriasis

Photo by naomish from unsplash

frequent, although there are very few published cases with lesions outside the skin and, to the best of our knowledge, none with glottic xanthogranulomas. However, exact diagnosis is difficult, and… Click to show full abstract

frequent, although there are very few published cases with lesions outside the skin and, to the best of our knowledge, none with glottic xanthogranulomas. However, exact diagnosis is difficult, and our case is a good example of that continuum in the xanthogranuloma family. Non-LCH represents a challenge for the clinician not only at the diagnostic level but also therapeutically. Given the rarity of these diseases, there is no consensus on treatment, and progressive forms often respond poorly. As the present case shows, waiting for spontaneous resolution is an option, even in widely disseminated presentations, as long as a delay of several years for the complete regression of the condition is acceptable.

Keywords: real world; line; treatment; biologic agent; world experience

Journal Title: International Journal of Dermatology
Year Published: 2021

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.